European Psychiatry - Volume 33 - March 2016

309 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S305
Methods Retrospective analysis of clinical files of patients admit-
ted to our hospital unit with FEP diagnosis from January/2012
to April/2015. Clinician-rated dimensions of psychosis symptom
severity scales (DSM-5) were applied.
Results Annual incidence of FEP was 11,3/100,000. From a total
of 755 patients, 57 (7,5%) corresponded to FEP; 38 (66,7%) were
diagnosed with SSP, 11 (19,3%) affective psychosis, 3 (5,2%) toxic
psychosis and 5 (8,8%) organic psychosis. Most were female
(61,4%), with a mean age of 49 years. The majority were unem-
ployed (66,7%), lived with family (57,9%), and presented with
moderate-severe delusions (80,1%), but without hallucinations
(57,8%), disorganized speech (59,6%) or negative symptoms (85,9%).
Affective FEP patients were older (61 vs 45 years), presented with
less severe psychotic symptoms (7,2 vs 8,3 points), but with higher
hospital admission (26,1 vs 21,1 days).
Conclusions Regardless the growing interest concerning FEP, its
conceptualization and characterization remains controversial. Our
results differ from pre-existing literature data, especially concern-
ing gender and age. By including all the possible etiologies of FEP,
we aimed to obtain a more realistic characterization of this entity
in a real-world setting.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW539
Neutrophin signalling in first-episode
psychosis: relationship with
treatment response 1 year after the
illness onset
M. Martinez-cengotitabengoa ∗, K. Macdowell , S. Alberich ,
M. Parellada , P. Saiz , R. Rodriguez , E. Berrocoso ,
M. Bernardo , A. Gonzalez-pinto , J.C. Leza
1 CIBERSAM-University Hospital of Alava- National Distance
Education University UNED, Psychiatry, Vitoria, Spain
2 CIBERSAM- Universidad Complutense de Madrid, Pharmacology,
Madrid, Spain
3 CIBERSAM- University Hospital of Alava, Psychiatry, Vitoria, Spain
4 CIBERSAM- Hospital General Universitario Gregorio Mara˜non-
Universidad Complutense de Madrid, Psychiatry, Madrid, Spain
5 CIBERSAM- Universidad de Oviedo, Psychiatry, Oviedo, Spain
6 CIBERSAM- Insituto de Investigacion 12 de Octubre, Psychiatry,
Madrid, Spain
7 CIBERSAM- Universidad de Cadiz, Pharmacology, Cadiz, Spain
8 CIBERSAM- Hospital Clinic y Universidad de Barcelona, Psychiatry,
Barcelona, Spain
9 CIBERSAM- University Hospital of Alava- University of the Basque
Country EHU-UPV, Psychiatry- Neurosciences, Vitoria, Spain
∗ Corresponding author.
Introduction Pro/antiinflammatory imbalance has been found
in first-episode psychotic (FEP) patients, even 12 months later.
Current research is every time more focused in the need to
find biomarkers to understand the underlying pathophysiological
mechanisms of this severe illness.
Objectives To assess peripherical levels of neurotrophins and
their receptors and their correlation with inflammation, clinical
symptomatology and response to antipsychotic treatment, over the
time.
Methodology Ninety-four FEP patients and 80 matched healthy
controls were included. Blood samples were taken at baseline to
measure BDNF and NGF and their receptor levels (TrkB-full, TrkB-
truncated and TrkA) and pro/antiinflammatory parameters (NFkB,
COX-2, iNOS, PPARgamma, 15d-PG12). Patients were followed-up
during 12 months.
Results BDNF TrkB-full receptor and NFG TrkA receptor levels
increased during the follow-up whereas BDNF TrkB-truncated
form receptor decreased. After adjusting for confounding vari-
ables, baseline levels of proinflamatory variables were significantly
related to TrkB-full/TrkB-truncated ratio (FL/T), suggesting that
a higher proinflammatory status is related to a higher FL/T ratio
expression. Furthermore, baseline FL/T ratio could have a predic-
tor role of patient’s functionality 1 year after the illness onset,
depending on whether patient is treated or not with antipsychotic
drugs.
Conclusion Inflammatory processes, neurotrophic pathways and
functional status of FEP patients seem to be relatedwhich is of great
traslational relevance. Specific, the expression of the 2 isoforms
of BDNF receptor should be taken into account before starting an
antipsychotic drug treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW540
Antipsychotic Medication Adherence
Scale (AMAS): Development and
preliminary psychometric properties
M.J. Martins ∗, A.T. Pereira , C.B. Carvalho , P. Castilho ,
A.C. Lopes , A. Oliveira , C. Roque , D. Mota , F. Tróia ,
M. Bajouco , N. Madeira , O. Matos , P. Santos , R. Leite ,
S. Morais , T. Santos , T. Santos , V. Nogueira , V. Santos ,
A. Macedo
1 University of Coimbra, CINEICC, faculty of psychology and
educational sciences, Coimbra, Portugal
2 University of Coimbra, department of psychological medicine,
Coimbra, Portugal
3 University of Azores, education department, Azores, Portugal
4 University of Coimbra, faculty of psychology and educational
sciences, Coimbra, Portugal
5 Baixo Vouga hospital centre, department of psychiatry and mental
health, Aveiro, Portugal
∗ Corresponding author.
Introduction Although being highly consensual that antipsy-
chotic adherence is an important outcome predictor in psychosis,
existing reviews have found mean rates of adherence around
40–60%. Several aspects, such as patient-related, medication-
related, environmental-related variables have been described as
important predictors.
Aims This study aim is to develop, administer and present pre-
liminary psychometric properties of a new scale for antipsychotic
medication adherence that includes different types of predictors
(clinical, psychosocial, and practical among others).
Methods The “AMAS” was developed by a multidisciplinary team
and was based on recent research on factors influencing antipsy-
chotic adherence. The scale evolved from multiple drafts and
experts were contacted in order to improve the final version.
Over 50 patients with a diagnosis of a psychotic-spectrum dis-
order taking antipsychotic medication will be assessed with the
“AMAS” and the Medication Adherence Rating Scale. Additionally,
each patient’s psychiatrist will fill in a form with demographic
and clinical variables (such as type of symptoms, previous adher-
ence problems, current adherence, insight and other relevant
variables).
Results This is an ongoing study and the sample is still being
collected (scheduled finish date: February/2016). Our statistical
analysis’ plan includes: reliability analysis (Chronbach’s alpha,
alpha if item deleted, inter item correlations and covariances and
item-total correlations); validity (convergent validity); factorial
analysis.
Conclusions It is hypothesized that the “AMAS” will be a prac-
tical, reliable and valid unidimentional instrument with clinical
utility assessing adherence to antipsychotics. The “AMAS” can be
also useful in assessing intervention targets (e.g. psychoterapeuti-
cal, psychoeducational) to enhance adherence.